NCT00937586

Brief Summary

The overall purpose of this research is to determine if certain genes increase the chance of developing prostate cancer and once diagnosed increase the chance of the prostate cancer spreading to other parts of the body.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,937

participants targeted

Target at P75+ for all trials

Timeline
13mo left

Started May 2000

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress96%
May 2000Jun 2027

Study Start

First participant enrolled

May 1, 2000

Completed
9.2 years until next milestone

First Submitted

Initial submission to the registry

July 10, 2009

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 13, 2009

Completed
17.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2027

Last Updated

December 17, 2025

Status Verified

December 1, 2025

Enrollment Period

27.1 years

First QC Date

July 10, 2009

Last Update Submit

December 15, 2025

Conditions

Prostate Cancer

Keywords

Metastatic Prostate CancerProstate Cancer Risk Assessment

Outcome Measures

Primary Outcomes (1)

  • Ability to recognize increased risk of metastatic prostate cancer based on specific genetic polymorphisms.

    At the time of prostate cancer diagnosis

Secondary Outcomes (1)

  • Ability to predict risk for treatment failure based on analysis of specific polymorphisms.

    At the time of prostate cancer diagnosis

Study Arms (1)

Newly diagnosed patients

Patients with newly diagnosed prostate cancer.

Eligibility Criteria

Age18 Years - 100 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with newly diagnosed prostate cancer are being recruited for this study from Siteman Cancer Center radiation oncology, medical oncology and urology clinics.

You may qualify if:

  • Newly diagnosed patients: 1. newly diagnosis of prostate cancer 2. untreated except for neoadjuvant systemic therapy.

You may not qualify if:

  • Newly diagnosed patients: 1. inability to give informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Whole blood, serum, white cells, prostate tissue.

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Officials

  • Bettina Drake, PhD

    Washington University School of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 10, 2009

First Posted

July 13, 2009

Study Start

May 1, 2000

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2027

Last Updated

December 17, 2025

Record last verified: 2025-12

Locations

US(1)